Podcasts about therapies

Send us Fan MailMost trials comparing CPAP and NIMV leave a lingering doubt about whether surfactant explained the difference. This one does not. Ben brings a multicenter noninferiority trial from JAMA Network Open in infants born between 24 and 29 weeks, randomized to nasal CPAP or NIMV with every baby receiving less invasive surfactant administration. The trial stopped early for futility after 312 infants. Noninvasive ventilation failure within 72 hours was 26 percent on CPAP versus 13 percent on NIMV. Ben and Daphna talk through what happens when surfactant is off the table, the unexpected NEC signal, and where the guidelines may need revisiting.----Nasal Continuous Positive Airway Pressure vs Nasal Intermittent Positive Pressure Ventilation in Preterm Infants With Respiratory Distress Syndrome: A Randomized Clinical Trial. Zhang H, Zhang Y, Zeng L, Tong X, Piao M, He H, Zhao C, Xie H, Zheng Z, Cui Q, Lai Y, Wang H, Wang L, Liu H, Tian X, Wu H, Kang L, Han T.JAMA Netw Open. 2026 Jun 1;9(6):e2619785. doi: 10.1001/jamanetworkopen.2026.19785.Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below.Enjoy!

Dr. Kyla Ortved helps horse owners understand joint therapies in senior horses. She is an Associate Professor of Large Animal Surgery at the University of Pennsylvania's New Bolton Center. Dr. Ortved is boarded in Surgery and Veterinary Sports Medicine & Rehabilitation.My Senior Horse - Episode 52 Guests and Links:Guests: Dr. Kyla Ortved, Associate Professor of Large Animal Surgery at the University of Pennsylvania's New Bolton CenterConnect with Host: Kimberly S. Brown of Editorial Director of My Senior Horse | Email Kim (kbrown@equinenetwork.com) | Follow Kim on LinkedIn (@kimberlylsbrown)

Send us Fan MailA term newborn looks fine on mom's chest, then crashes within minutes. By the time transport arrives, there's a pH of 6.9, a lactate over 10, and a baby already intubated and on surfactant. Is this pulmonary hypertension, congenital heart disease, or something else entirely? In this episode of From the Heart, It's Complicated, Dr. Adrianne Bischoff and Dr. Nim Goldshtrom work through a real, complex neonatal cardiac case in real time — the kind of case that keeps neonatologists up at night. They break down how to clinically differentiate PPHN from congenital heart disease with limited data, why epinephrine's response mattered more than the blood pressure number, how therapeutic hypothermia can unmask cardiac dysfunction, and why "blue is always better than gray" when managing a shunt-dependent circulation. Along the way: real literature, real physiology, and the reasoning behind decisions made under pressure, with a surprise diagnosis at the end. Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below.Enjoy!

Nature staff discuss how an FDA-approved drug for narcolepsy could have promise beyond the condition, and the longest-lived human brain organoids yet.00:28 The promise of a new narcolepsy drugNature: First-of-its-kind narcolepsy drug opens door to new therapies for the brain05:53 Human brain organoids kept alive for over five yearsNature: Human organoids that mimic brain development grown for years in lab​​​​​​​Subscribe to Nature Briefing, an unmissable daily round-up of science news, opinion and analysis free in your inbox every weekday. Hosted on Acast. See acast.com/privacy for more information.

Send us Fan MailWhy does reading in the NICU still feel optional when the evidence says otherwise? Daphna sits down with Paige Pedroli, author of the Nic Zoo book and two-time NICU mom, and Dr. Raquel Garcia, a craniofacial and feeding specialist, to unpack why reading to preterm and critically ill infants belongs alongside kangaroo care as neuropromotive, not just neuroprotective. They cover the evidence behind auditory stimulation and language outcomes, why reading gives overwhelmed parents a real role in their baby's care, and how units can build low-cost reading programs with book libraries and student volunteers. A practical, moving conversation for anyone building developmental care into daily NICU practice. Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below.Enjoy!

Why treating the cell, not the protein, could turn chronic disease treatment into something closer to a cure. You've built single-cell pipelines that spit out clusters, p-values and target lists, but nothing that survives contact with the clinic. What if the clustering method itself is quietly leading you astray? Adam Freund is Founder and CEO of Arda Therapeutics, a biotech using single-cell sequencing to find the pathogenic cells driving chronic disease. He spent seven years as a Principal Investigator at Calico Life Sciences, building a research lab on the biology of ageing and helping grow the company from 15 to more than 200 people, and holds a PhD in Molecular and Cell Biology from UC Berkeley. You'll get a working model for how Arda's discovery engine turns single-cell and spatial transcriptomic data into causal cell targets. Adam explains why a common statistical shortcut in single-cell analysis produces disease signals that don't hold up and how cell depletion could replace daily dosing with a handful of treatments that reset the immune system. Ross and Adam cover how Arda finds pathogenic cell populations across hundreds of donors, why chi-squared tests on cell clusters can substitute cell count for donor count without anyone noticing, and how B-cell depletion therapies proved that removing a cell can beat blocking its pathway. This one is for data science leaders and computational biologists building single-cell pipelines, not listeners after a general intro to drug discovery. Key Takeaways - Chi-squared tests on cell clusters draw their statistical power from the number of cells, not the number of donors, so a single oversampled patient can produce the same p-value as a hundred-donor study. - Rituximab clears 100% of B cells from circulation yet does nothing for lupus because the disease-driving cells live in tissue, not blood, a lesson now shaping where Arda tests its own molecules. - Neighborhood analysis scores each cell by the donor identity of its nearest neighbours rather than forcing cells into predefined clusters, producing a continuous disease-enrichment map with no cluster boundaries. - When depleted cells regrow, they often come back without the trait that made them harmful in the first place, which means a handful of doses can hold a chronic disease in remission for months. Chapter Markers 00:00 Why cell depletion beats pathway blocking 01:05 Welcome Adam Freund to the show 01:30 From Calico Life Sciences to founding Arda 03:29 Why blocking one pathway rarely works 05:32 B-cell depletion as the proof of concept 08:14 Building a modular library of depletion tools 10:46 Single-cell sequencing removes the need for a hypothesis 11:43 Why clustering is a dial, not ground truth 15:24 The chi-squared trap in single-cell analysis 20:40 Neighbourhood analysis and donor-weighted scoring 23:44 Moving from enrichment to causality 26:32 Inside Arda's lead fibrosis program 30:33 Why solid tissue testing beats blood samples 34:25 Simulating depletion in spatial transcriptomic data 38:49 The case for intermittent dosing over daily pills 43:58 The data infrastructure behind Arda's platform 48:46 Where spatial and protein data are heading Useful Links & Resources - Adam Freund on LinkedIn: https://www.linkedin.com/in/adam-freund-0657654 - CorrDyn: https://corrdyn.com Connect With the Show - Host Ross Katz on LinkedIn: https://www.linkedin.com/in/b-ross-katz/ - Host Ross Katz on X: https://x.com/brosskatz - CorrDyn on LinkedIn: https://www.linkedin.com/company/corrdyn/ If your team runs single-cell pipelines, how do you currently decide on the number of clusters, and have you ever checked whether your significance scales with donor count rather than cell count? Tell us in the comments; we're building a running list of data QA checks for biotech data science teams. Visit corrdyn.com to learn how CorrDyn can help your organization extract value from data.

View the Show Notes Page for This Episode Become a Member to Receive Exclusive Content Sign Up to Receive Peter's Weekly Newsletter In this episode, Peter sits down with Dr. Linus Abrams, a psychiatrist with nearly 35 years of clinical experience specializing in mood disorders and psychopharmacology, to explore how our understanding of mental health is evolving beyond the traditional neurotransmitter model. After decades in practice, Linus began questioning many of the assumptions underlying modern psychiatry, leading him to investigate how hormones, metabolism, inflammation, circadian biology, and the endocrine system shape mood and cognition. Together, Peter and Linus examine why psychiatric care should aim not only to reduce symptoms but also to restore the full human experience. They discuss how psychiatric medications work, where they fall short, and why distinguishing bipolar disorder from unipolar depression is essential for effective treatment. The conversation also explores the growing mental health burden of social isolationn associated with digital devices and social media, along with the biological factors—nutrition, exercise, sleep, and chronic stress—that influence resilience and distress tolerance. Linus explains the powerful roles of estrogen, progesterone, testosterone, and thyroid hormone in regulating mood and cognition across the lifespan. Finally, Peter and Linus review the promise and limitations of ketamine and psychedelic therapies, and why the future of psychiatry may lie in integrating neuroscience, endocrinology, and whole-body physiology to better understand, diagnose, and treat mental illness. We discuss: Linus's passion for understanding his patients and going beyond traditional psychiatry [2:45]; A short primer on the different classes of drugs used in psychiatry [12:45]; Evaluation of a patient with bipolar disorder [26:00]; An evolutionary perspective on depression [33:30]; Changes in the modern world triggering mental health problems [41:00]; An evolutionary perspective on insomnia [48:15]; Peter's window analogy to understand distress tolerance and irritability [49:45]; The impact of foundational biological factors on psychiatry: nutrition, exercise, sleep, and endocrinology [52:30]; The effect of estradiol on neurotransmitters in the brain [58:15]; Options for increasing testosterone in men, and why clomiphene is inferior to exogenous testosterone [1:11:00]; The rapid drop in progesterone is linked to both premenstrual dysphoric disorder (PMDD) and postpartum depression [1:14:30]; Treatment of postpartum depression [1:18:00]; Hypothyroidism presenting as depression: how Linus makes the diagnosis and what he uses for treatment [1:26:00]; The link between hyperarousal and chronically elevated cortisol [1:39:30]; A case where the menopause transition uncovers bipolar disorder [1:44:15]; Ketamine as a tool to treat recalcitrant depression, and concerns about its recreational use [1:49:15]; Case study: an Alzheimer's patient who improved after psilocybin, and why Linus is cautious about drawing conclusions from it [1:55:15]; Peter's experience with psychedelics, and the myth that estrogen is bad for men [2:00:30]; The therapeutic potential of psychedelics in psychiatry [2:11:00]; and More. Connect With Peter on Twitter, Instagram, Facebook and YouTube

Send us Fan MailIs your EMR actually built for neonatology, or just retrofitted to survive it? Ben sits down with Dr. Lindsey Knake, clinical assistant professor and associate chief health information officer at the University of Iowa, to talk AI in the NICU. They cover the real difference between Epic's homegrown tools and third-party options like Evidently and NABLA, why a six-month hospital stay breaks most chart summarization tools, and how ambient AI is starting to change documentation and family counseling. Lindsey also shares practical paths into clinical informatics for clinicians without a coding background. A grounded look at where NICU technology actually stands right now. Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below.Enjoy!

Send us Fan MailThe full week of Journal Club in one place. Monday, the PLaNT trial of prophylactic CPAP for late preterm infants born by cesarean, with senior author Dr. Edgardo Szyld. Tuesday, whether parental holding during therapeutic hypothermia changes feeding and length of stay. Wednesday, the Connection Study, the first live biotherapeutic product tested under an IND, and what it means for probiotics returning to the NICU. Thursday, a handheld light probe that reads bowel through the skin to catch NEC before the X-ray does. Friday, Dr. Dinushan Kaluarachchi on the respiratory severity score and what its trajectory tells us.----First-in-human pilot study of broadband optical spectroscopy (BOS) as noninvasive surveillance for necrotizing enterocolitis (NEC). Dodd AC, Lehane AJ, Lee A, Hurlock A, Su Y, Ilahi I, Lautz TB, Backman V, Goldstein SD.J Pediatr Surg. 2026 May;61(5):162978. doi: 10.1016/j.jpedsurg.2026.162978. Epub 2026 Feb 3.PMID: 41643767Association of parental holding during therapeutic hypothermia and NICU outcomes for infants with hypoxic-ischemic encephalopathy. Nguyen TT, Glass HC, Chan N, Taketa E, Pineda R, Cornet MC, Miller MJ.J Perinatol. 2026 Jun 22. doi: 10.1038/s41372-026-02753-3. Online ahead of print.PMID: 42332041Live biotherapeutic product IBP-9414 (L. reuteri) in very low birth weight infants: the Connection Study. Neu J, Del Moral T, Guthrie SO, Hudak ML, Indrio F, Kim JH, Kronström A, Martin CR, Modi N, Rastad J, Schnitzer TJ, Singh R, Strömberg S, Szajewska H, Thuresson M, Caplan M.Pediatr Res. 2026 Feb 20. doi: 10.1038/s41390-026-04826-7. Online ahead of print.PMID: 41721054Prophylactic CPAP at Cesarean Birth in Late-Preterm Newborns: A Multicenter RCT. Shah BA, DeShea L, Schmölzer GM, Josephsen JB, Fabres J, Wetzel EA, Rykovich H, Thomas A, Law B, Garrido C, Szyld E.Pediatrics. 2026 Aug 1;158(2):e2025070998. doi: 10.1542/peds.2025-070998.PMID: 42457181 Clinical Trial.Association Between Delivery Room Continuous Positive Airway Pressure and Neonatal Outcomes in Late Preterm and Term Infants: A Systematic Review and Meta-Analysis. Chin Y, Hill M, Sett A, Thomas N, Razak A.J Paediatr Child Health. 2026 Jul 28. doi: 10.1111/jpc.70516. Online ahead of print.PMID: 42517258 Review.Bronchopulmonary Dysplasia Definition Based on Respiratory Severity Score. Kaluarachchi DC, Peebles PJ, Lasarev MR, Guthrie SO, Laughon MM.Pediatr Pulmonol. 2026 Jul;61(7):e71750. doi: 10.1002/ppul.71750.PMID: 42478108 Free PMC article. No abstract available.Respiratory severity score patterns by birth gestational age among a cohort of extremely preterm infants. Peebles PJ, Lasarev MR, Guthrie SO, Laughon MM, Keller RL, Kaluarachchi DC.J Perinatol. 2026 Jun 29. doi: 10.1038/s41372-026-02778-8. Online ahead of print.PMID: 42374145 No abstract available.Respiratory severity score as a predictor for need for tracheostomy in infants with severe bronchopulmonary dysplasia. Kaluarachchi NM, Afah Annah S, Lasarev MR, Peebles PJ, Kaluarachchi DC.J Perinatol. 2026 Jun 25. doi: 10.1038/s41372-026-02720-y. Online ahead of print.PMID: 42350618 No abstract available.Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below.Enjoy!

Send us Fan MailThe respiratory severity score is one multiplication most of us already do in our heads, mean airway pressure times FiO2. This week Dr. Dinushan Kaluarachchi joins Journal Club to walk through three papers built on it, RSS trajectories across gestational age in the PROP cohort, an RSS based grading of BPD at 36 weeks, and RSS after 40 weeks as a predictor of tracheostomy. He also talks about writing that last paper with his son, a high school junior, and why a brief communication is a realistic on-ramp for students. Plus a preview of two upcoming trials, including surfactant given through a supraglottic airway.https://www.nature.com/collections/ejaffajdhi----Bronchopulmonary Dysplasia Definition Based on Respiratory Severity Score. Kaluarachchi DC, Peebles PJ, Lasarev MR, Guthrie SO, Laughon MM.Pediatr Pulmonol. 2026 Jul;61(7):e71750. doi: 10.1002/ppul.71750.PMID: 42478108 Free PMC article. No abstract available.Respiratory severity score patterns by birth gestational age among a cohort of extremely preterm infants. Peebles PJ, Lasarev MR, Guthrie SO, Laughon MM, Keller RL, Kaluarachchi DC.J Perinatol. 2026 Jun 29. doi: 10.1038/s41372-026-02778-8. Online ahead of print.PMID: 42374145 No abstract available.Respiratory severity score as a predictor for need for tracheostomy in infants with severe bronchopulmonary dysplasia. Kaluarachchi NM, Afah Annah S, Lasarev MR, Peebles PJ, Kaluarachchi DC.J Perinatol. 2026 Jun 25. doi: 10.1038/s41372-026-02720-y. Online ahead of print.PMID: 42350618 No abstract available.Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below.Enjoy!

In this episode, Danielle Roman, PharmD, BCOP, and Jordan Hill, PharmD, BCOP, discuss optimal care for patients with HR-positive/HER2-negative breast cancer receiving newer oral targeted therapies. Their conversation addresses treatment selection across early-stage and metastatic disease, biomarker-informed decision-making, adverse event management, and practical strategies to help patients remain on therapy. Key topics include: Selecting and sequencing oral targeted therapies, including CDK4/6 inhibitors, PARP inhibitors, PI3K/AKT pathway inhibitors, and oral SERDs Identifying patients with high-risk early breast cancer and applying evidence from trials such as monarchE, NATALEE, and OlympiA Using biomarkers such as BRCA1/2, PIK3CA, AKT1, PTEN, and ESR1 to guide therapy in metastatic disease Monitoring and managing treatment-related adverse events, including neutropenia, diarrhea, hepatotoxicity, QTc prolongation, hyperglycemia, rash, stomatitis, anemia, nausea, and fatigue Using dose modification, supportive care, patient education, and proactive follow-up to improve adherence and persistence with oral therapy Incorporating oncology pharmacists and the multidisciplinary care team into ongoing treatment monitoring and patient support PresentersDanielle Roman, PharmD, BCOP Manager, Oncology Clinical Pharmacy Services Oncology Clinical Pharmacy Specialist Allegheny Health Network Pittsburgh, Pennsylvania Jordan Hill, PharmD, BCOP Clinical Pharmacy Specialist, Breast Oncology West Virginia University Cancer Institute Morgantown, West Virginia Get access to all of our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify. Access the full educational program: Link to full program:https://bit.ly/4gvZerW And be sure to try our Interactive Decision Support Tools for Early Breast Cancer and Selecting AKT or PI3K Inhibitors for Patients With Metastatic Breast Cancer. By answering just a few quick questions, you can see what 5 experts would recommend for specific patient scenarios. Early Breast Cancer:https://bit.ly/4gtUiUq AKT or PI3K Inhibitors in MBC:https://bit.ly/4qcyBvk Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Send us Fan MailNEC still tends to announce itself on an X-ray, usually later than we want. This week Daphna reviews the first-in-human study of broadband optical spectroscopy, a handheld transcutaneous probe out of Lurie Children's that reads reflected light from 350 to 2500 nanometers to look at bowel beneath the skin. Just under 100 preterm infants, more than 11,000 scans, and a machine learning model that separated NEC from non-NEC scans with 100% sensitivity and a 100% negative predictive value, though the positive predictive value sat at 24%. Ben and Daphna work through what the curves actually show and what would have to come next.----First-in-human pilot study of broadband optical spectroscopy (BOS) as noninvasive surveillance for necrotizing enterocolitis (NEC). Dodd AC, Lehane AJ, Lee A, Hurlock A, Su Y, Ilahi I, Lautz TB, Backman V, Goldstein SD.J Pediatr Surg. 2026 May;61(5):162978. doi: 10.1016/j.jpedsurg.2026.162978. Epub 2026 Feb 3.PMID: 41643767Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below.Enjoy!

Send us Fan MailProbiotics left US NICUs after the FDA reclassified them, and NEC rates went up. This week Ben reviews the Connection Study, a 2,158 infant phase 3 trial of IBP-9414, a live biotherapeutic product containing Limosilactobacillus reuteri, run under an IND with the regulatory rigor probiotics never had. Neither primary endpoint reached significance, but all cause mortality fell 27%, and surgically confirmed NEC favored treatment after 14 days of dosing. The discussion may be the real story, including a kappa of 0.36 between radiologists reading the same NEC films. Ben and Daphna talk through what a regulated probiotic would mean for the babies waiting now.----Live biotherapeutic product IBP-9414 (L. reuteri) in very low birth weight infants: the Connection Study. Neu J, Del Moral T, Guthrie SO, Hudak ML, Indrio F, Kim JH, Kronström A, Martin CR, Modi N, Rastad J, Schnitzer TJ, Singh R, Strömberg S, Szajewska H, Thuresson M, Caplan M.Pediatr Res. 2026 Feb 20. doi: 10.1038/s41390-026-04826-7. Online ahead of print.PMID: 41721054Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below.Enjoy!

Dhineli Perera speaks with infectious diseases physician Josh Davis about the management of acute COVID-19 in the community. They discuss the major risk factors for severe disease, the evidence behind oral antiviral therapies, and the patients most likely to benefit from treatment. Read the full article in Australian Prescriber.

Welcome to The Animal Chiropractic Clinic Chatter Podcast!

Send us Fan MailParents of babies undergoing therapeutic hypothermia often wait days before they can hold their child, and many never get the chance during cooling at all. This week on Journal Club, Daphna reviews a new Journal of Perinatology retrospective cohort from two level IV NICUs, 379 infants with HIE, where 28% were held during cooling. Held infants reached full oral feeds sooner, were more likely to go home on breast milk, and had shorter stays, but they were also less sick to begin with. Ben pushes on confounding, on the exclusion of infants who died, and on what equipment would make holding routine.----Association of parental holding during therapeutic hypothermia and NICU outcomes for infants with hypoxic-ischemic encephalopathy. Nguyen TT, Glass HC, Chan N, Taketa E, Pineda R, Cornet MC, Miller MJ.J Perinatol. 2026 Jun 22. doi: 10.1038/s41372-026-02753-3. Online ahead of print.PMID: 42332041Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below.Enjoy!

Ketogenic and low-carbohydrate diets often focus on a specific carbohydrate target: keep your net carbs under 30 grams. But as registered dietitian and certified diabetes educator Franziska Spritzler demonstrates in this presentation from Metabolic Health Summit, a carbohydrate target is not a therapy. Effective implementation means a full assessment of medical history, medications, labs, food preferences, lifestyle, and the motivation that will carry a patient through year one and beyond.Spritzler specializes in low-carbohydrate and ketogenic nutrition and has extensive experience helping people use these approaches to improve metabolic health. The creator of lowcarbdietitian.com, she walks through the practical decisions clinicians face: when a ketogenic diet is warranted versus a more flexible low-carbohydrate approach, why she recommends 1.2 to 1.8 grams of protein per kilogram rather than the RDA's 0.8, how to manage medication adjustments for patients at risk of hypoglycemia or hypotension, and how to handle electrolytes, carbohydrate counting, sweeteners, and plant-based variations without losing the patient along the way.Questions Answered in This Episode:• What actually separates a ketogenic diet from a low-carbohydrate diet, and when does the difference matter?• Why is the protein RDA too low for long-term metabolic health, and what range does Spritzler recommend instead?• Who should avoid ketogenic diets entirely, and why are most contraindications manageable with closer supervision?• How should medications be monitored and adjusted when a patient begins carbohydrate restriction?• Should patients count net carbs or total carbs, and why are packaged "net carb" labels unreliable?• Can a ketogenic diet be done as a vegetarian or vegan?A practice-tested blueprint for turning carbohydrate restriction from a prescription into a therapy patients can sustain.Special thanks to the sponsors of this episode:✅ Genova Connect: Get 15% off any Genova Connect test kit with code METABOLICLINK here.✅ iRestore: Get a special discount on the iRestore Illumina Face Mask with code LINK here.✅ fatty15: Get an additional 50% off a 90-day subscription starter kit with code METABOLICLINK.✅ Zocdoc: Find and instantly book a top-rated doctor here.More Links• Franziska's website: lowcarbdietitian.com• The Metabolic Initiative (expert lectures, CME, ad-free episodes, live Q&As; first 7 days free): membership.metabolicinitiative.comIn every episode of The Metabolic Link, we'll uncover the very latest research on metabolic health and therapy. If you like this episode, please share it, subscribe, follow, and leave us a comment or review on whichever platform you use to tune in!You can find us on all your major podcast players here and full episodes are also up on our Metabolic Health Summit YouTube channel!In every episode of The Metabolic Link, we'll uncover the very latest research on metabolic health and therapy. If you like this episode, please share it, subscribe, follow, and leave us a comment or review on whichever platform you use to tune in!You can find us on all your major podcast players here and full episodes are also up on our Metabolic Health Summit YouTube channel!Find us on social: InstagramFacebookYouTubeLinkedInPlease keep in mind: The Metabolic Link does not provide medical or health advice, but rather general information that does not serve as a substitute for a licensed healthcare professional. Never delay in seeking medical advice from an appropriately licensed medical provider for any health condition that you may have.

Send us Fan MailLate preterm babies born by cesarean fill our NICUs, and most of them are there for respiratory distress that resolves in a day or two. Could 20 minutes of CPAP in the operating room keep them out? This week on Journal Club, Ben and Daphna break down the PLaNT trial, a five center randomized pilot of prophylactic CPAP at 5 to 6 cm of water in spontaneously breathing infants born at 34 to 36 weeks by cesarean. They then sit down with senior author Dr. Edgardo Szyld to talk pneumothorax risk, the 35 to 36 week subgroup, consenting families, and what PLaNT 2 must prove.----Prophylactic CPAP at Cesarean Birth in Late-Preterm Newborns: A Multicenter RCT. Shah BA, DeShea L, Schmölzer GM, Josephsen JB, Fabres J, Wetzel EA, Rykovich H, Thomas A, Law B, Garrido C, Szyld E.Pediatrics. 2026 Aug 1;158(2):e2025070998. doi: 10.1542/peds.2025-070998.PMID: 42457181 Clinical Trial.Association Between Delivery Room Continuous Positive Airway Pressure and Neonatal Outcomes in Late Preterm and Term Infants: A Systematic Review and Meta-Analysis. Chin Y, Hill M, Sett A, Thomas N, Razak A.J Paediatr Child Health. 2026 Jul 28. doi: 10.1111/jpc.70516. Online ahead of print.PMID: 42517258 Review.Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below.Enjoy!

In this insightful episode of Parallax, Dr Ankur Kalra is joined by Dr Barry Borlaug, Professor of Cardiology at Mayo Clinic and one of the world's leading experts in cardiac haemodynamics, for a comprehensive discussion on the evolving landscape of heart failure with preserved ejection fraction (HFpEF). Together, they explore the complexities of diagnosing and managing a syndrome that continues to challenge clinicians. Dr Borlaug explains why exercise right-heart catheterisation remains the gold standard for uncovering "hidden" HFpEF, particularly in patients with normal resting filling pressures, and provides a detailed overview of the Mayo Clinic's invasive exercise testing protocol. The conversation also traces the evolution of HFpEF phenotyping, from the traditional hypertensive patient to the increasingly recognised obesity-driven phenotype, highlighting the role of systemic inflammation, visceral adiposity and disease progression across the HFpEF spectrum. Dr Borlaug outlines what he describes as the modern therapeutic backbone for HFpEF in 2026, reviewing the evidence supporting SGLT2 inhibitors, mineralocorticoid receptor antagonists including finerenone, and incretin-based therapies such as semaglutide and tirzepatide. Looking ahead, he discusses emerging investigational approaches including sotatercept, the challenges facing device-based therapies, and the importance of identifying HFpEF mimics such as cardiac amyloidosis and hypertrophic cardiomyopathy to ensure patients receive the most appropriate treatment. Questions and comments can be sent to "podcast@radcliffe-group.com" and may be answered by Ankur in the next episode. Host: @AnkurKalraMD and produced by: @RadcliffeCardio Parallax is Ranked in the Top 100 Health Science Podcasts (#48) by Million Podcasts.

Learn which therapies actually work for adolescent boys struggling with depression, why residential treatment is sometimes recommended, and the critical role parents play in long-term recovery.Learn more at: https://missionprephealthcare.com/locations/california/rancho-palos-verdes-palos-verdes-dr/ Mission Prep City: San Juan Capistrano Address: 30310 Rancho Viejo Rd. Website: https://missionprephealthcare.com/

In this podcast episode, Gilles Salles, MD, PhD, and Pier Luigi Zinzani, MD, PhD, discuss the role of new and emerging targeted therapies in the management of patients with DLBCL, including: Overview of Unmet Needs With Current Standard of Care in DLBCL Expanding Role of Novel Agents in DLBCL  Access to Targeted Therapies and Clinical Trials in Non-Academic DLBCL Practice  Key Ongoing Trials of new and novel agents in DLBCL  Key Presentations/Results at EHA 2026 in DLBCL Presenters:  Gilles Salles, MD, PhD Service Chief, Lymphoma Service Steven Greenberg Chair Memorial Sloan Kettering Cancer Center Weill Cornell University New York, New York Pier Luigi Zinzani, MD, PhD Professor of Hematology Alma Mater Studiorum-University of Bologna Head, “Seràgnoli” Institute of Hematology IRCCS Azienda Ospedaliero-Universitaria di Bologna Department of Medical and Surgical Sciences Bologna University School of Medicine Bologna, Italy Link to full program:https://bit.ly/4gmyoS7 Get access to all of our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode with Anju Jaggi, we discuss a case study she recently completed on a dancer with atraumatic shoulder instability. We explore:Difference between traumatic and atraumatic stabilityPrevious imaging, use of MRarthrogram and role of imaging in shoulder instabilityObjective examination of an unstable shoulder Special testing of an unstable shoulderTreatment of the unstable shoulder

In this episode of Oncology Unplugged, host Chandler Park, MD, a medical oncologist at Norton Cancer Institute in Louisville, Kentucky, was joined by Stephen V. Liu, MD, the division chief of Hematology Oncology at MedStar Georgetown University Hospital, part of the MedStar Georgetown Cancer Institute, in Washington, DC.Their discussion centered on the continued evolution of precision medicine in non–small cell lung cancer (NSCLC), highlighting advances in molecular testing, targeted therapies, immunotherapy, and emerging treatment strategies presented at the 2026 ASCO Annual Meeting. Drs Park and Liu explored how lung cancer has become a model for precision oncology and emphasized that therapeutic advances across multiple tumor types have collectively shaped the current treatment landscape. They discussed the importance of understanding oncogenic drivers, overcoming resistance mechanisms, and moving effective therapies into earlier-stage disease to improve long-term patient outcomes.

On today's Good Day Health Show - ON DEMAND…Host Doug Stephan and Frankie Boyer (frankieboyer.com) have an engaging conversation about what it really takes to age well. Together, they discuss the importance of science-based medicine, why personalized blood testing can reveal far more than guesswork, and how hormones like testosterone and DHEA influence energy, longevity, and overall wellness. They also examine the impact of lifestyle choices, food ingredients, and the pharmaceutical industry's role in shaping public health information. Doug and Frankie encourage listeners to become informed advocates for their own health by asking questions, understanding their lab work, and making evidence-based decisions.Key Takeaways:Blood testing provides valuable insight into individual health needs and hormone balance.Hormones such as testosterone and DHEA play important roles in both men's and women's health.Healthy aging depends on lifestyle choices alongside personalized medical care.Consumers should evaluate health information critically and seek evidence-based guidance.Understanding what goes into food and personal care products can help support long-term wellness.For more on Good Day Health…Website: GoodDayHealthShow.comSocial Media: @GoodDayNetworks

Send us Fan MailWhen is surfactant "early," and when is it too early, or too late? In this second installment of our two-part series with the Neonatal Resuscitation Symposium, Ben Courchia sits down with Dr. Roger Soll, a leading voice in surfactant research since the 1980s, to trace how our thinking on timing has evolved, from aggressive prophylactic dosing to selective rescue therapy to today's less invasive approaches like LISA and SALSA. Dr. Soll unpacks why head-to-head trials keep favoring less invasive administration over InSurE, and how the rise of "nanopreemies" is quietly pulling the pendulum back toward earlier treatment. The conversation also touches on video laryngoscopy and aerosolized surfactant's unfulfilled promise. A candid, technically rich conversation for anyone who has stood at a warmer wondering whether, and when, to reach for surfactant. Dr. Soll expands on these themes at the Neonatal Resuscitation Symposium, September 10 to 11, 2026, at Indiana University School of Medicine. Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below.Enjoy!

Today's guest is Dr. Natalie Trehan, assistant professor at the Medical University of South Carolina and a clinician educator specializing in oral medicine, orofacial pain, and injectable therapies. As a scleroderma patient myself, I know how tough it is to find a dentist who actually understands our needs. Dr. Trehan shares practical tips that will help so many warriors, including one smart strategy for finding the right dentist.

Send us Fan MailWhich babies with critical congenital heart disease face the highest risk of brain injury, and does earlier surgery actually help? Why is infant CHD mortality climbing again after years of decline, and who's most affected? Can a mother's cardiovascular status in preeclampsia predict her newborn's circulatory transition? This week's Journal Club brings together five conversations on CHD, maternal-fetal physiology, and vaccine policy. Nim and Adrianne cover a meta-analysis on brain injury in critical CHD, a 25-year national mortality study, a pilot study on preeclampsia and neonatal cardiac output, and a look at RV diastolic function after CHD intervention. Ben and Eli close with Neo News on a controversial hepatitis B vaccine trial in Guinea-Bissau.Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below.Enjoy!

Are you a middle aged woman on the top of your career in a high-stakes environment? Maybe you are the one everyone depends on—meeting deadlines and managing teams with outward grace. But internally, the cost of "over-functioning" and now redesigning your role with AI in mind, has become unsustainable. If traditional productivity hacks like time-blocking and mindset reframes are making you feel worse,  if rest makes you feel guilty, it's time to look beneath the surface. In this episode, Dr. Julie Merriman explains why midlife burnout is a nervous system injury, not a lack of discipline. We dive into how somatic therapies and grounding help professional women move away from the urgency of "pushing through" to build a foundation of genuine internal calm.  You'll learn why chronic exhaustion physically blocks the cognitive flexibility needed for new digital tools and how to set boundaries based on your actual physiological capacity rather than just willpower.  Join us for a conversation about reclaiming your energy and approaching your next career chapter from a state of regulation and radiance, instead of guilt and exhaustion. Topics covered: symptoms of burnout in professional women, somatic therapy for stress, high achieving women over 50 burnout, nervous system regulation, compassion fatigue in leadership, midlife career reinvention stress, productivity advice for exhausted women, cognitive flexibility and AI, how to stop over functioning at work, signs of nervous system overwhelm, somatic healing for executives, burnout recovery for women 50 plus, why is time blocking not working Watch this episode here: https://youtu.be/rzUR9FAdt6A Find Julie Merriman here: https://www.juliemerrimanphd.com/  

Send us Fan MailIn this episode of Neo News, Ben and Eli break down a troubling story in vaccine policy: an unsolicited $1.6 million CDC grant funding a Danish research group's trial in Guinea-Bissau, one designed to withhold or delay the hepatitis B birth dose from thousands of newborns in a country where the disease is highly endemic. They trace the ethical parallels to Tuskegee, the funding irregularities, and the pushback from the Africa CDC that halted the study. They also cover the clinical stakes clinicians face daily, including age-dependent chronicity and the real risks of a "safe" two-month delay. A candid, unfiltered conversation about advocating for evidence-based care when the evidence itself becomes politicized.Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below.Enjoy!

Send us Fan MailIn this prospective study, Adrianne and Nim dig into an area with almost no normative pediatric data: right ventricular diastolic function. Comparing 57 infants with RV pressure overload after intervention for pulmonic stenosis or tetralogy of Fallot to 134 healthy controls, the authors found a consistent pattern, reduced beat-to-beat variability, a higher atrial contribution to filling, and an E/A ratio inversion that was nearly universal in the CHD group versus about half of controls. It's one of the first real attempts to define what a right-sided diastolic pattern actually looks like in this population. But without a comparison against cardiac catheterization, the hosts agree the findings are hypothesis-generating at best, a starting point for a multi-parametric approach, not a reason to skip an invasive workup.----Echocardiographic Markers of Right Ventricle Diastolic Dysfunction in Neonates and Infants with Congenital Heart Disease. Cantinotti M, Capponi G, Scalese M, Palladino E, Giordano R, Franchi E, Viacava C, Corana G, Marchese P, Pizzuto A, Assanta N, Santoro G. J Clin Med. 2025 Dec 23;15(1):98. doi: 10.3390/jcm15010098. PMID: 41517351 Free PMC article.Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below.Enjoy!

In today's episode, we spoke with Tanios S. Bekaii-Saab, MD. Dr Bekaii-Saab is the David F. and Margaret T. Grohne Professor of Novel Therapeutics for Cancer Research I, at the Mayo Clinic College of Medicine and Science, the division chair of Hematology/Medical Oncology at Mayo Clinic, and co-leader of the Advanced Clinical and Translational Science Program and the disease group leader for Gastrointestinal Cancers for the Mayo Clinic Comprehensive Cancer Center in Phoenix, Arizona.In our exclusive interview, Dr Bekaii-Saab discussed findings from the final analysis of cohort 3 of the phase 3 BREAKWATER trial (NCT04607421), which were presented at the 2026 ASCO Annual Meeting. These data showed that encorafenib (Braftovi) plus cetuximab (Erbitux) and FOLFIRI (leucovorin, 5-fluorouracil, and irinotecan) significantly improved outcomes compared with standard of care in patients with BRAF V600E–mutant metastatic colorectal cancer (mCRC), building on previously reported data from the trial that led to the February 2026 full FDA approval of encorafenib plus cetuximab and modified FOLFOX6 (leucovorin calcium, fluorouracil, and oxaliplatin) for this patient population. He also highlighted promising bispecific agents targeting VEGF and PD-1, as well as the promise of KRAS G12C inhibitors like calderasib (MK-1084) and sotorasib (Lumakras). Finally, he emphasized that minimal residual disease testing is prognostic and potentially predictive, and can aid in personalized mCRC management.

Send us Fan MailIn this small prospective pilot study, Adrianne and Nim explore a domain rarely discussed on rounds, how a mother's cardiovascular function in preeclampsia shapes her newborn's circulatory transition. Using maternal echo and neonatal electrical cardiometry across 13 mother-baby dyads, the authors found an inverse relationship: the worse the mother's cardiac function, the higher the neonate's cardiac output, though vascular tone barely budged. It's a compelling hypothesis about placental strain and fetal adaptation. But Nim pushes back hard on the methodology, pairing this paper with a companion study showing electrical cardiometry consistently overestimates cardiac output in neonates, and questioning why daily echoes were performed on these babies but the results never reported.----Linking maternal and neonatal circulation in preeclampsia. Piani F, Annesi L, Degli Esposti D, Vincenzi S, De Crescenzo S, Della Gatta AN, Simonazzi G, Corvaglia L, Martini S.Am J Physiol Heart Circ Physiol. 2026 Mar 1;330(3):H708-H716. doi: 10.1152/ajpheart.00945.2025. Epub 2026 Jan 12.PMID: 41525138 Free article.Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below.Enjoy!

New, Advanced Therapies in Gout explores the rapidly evolving therapeutic landscape beyond conventional urate-lowering therapy. Join our expert panel as they discuss emerging approaches—including cytokine inhibition, uricase therapies, NLRP3 and URAT-1 inhibitors, and the potential role of GLP-1 receptor agonists and SGLT2 inhibitors—while addressing which patients are most likely to benefit, how these agents fit into current treatment algorithms, and whether novel mechanisms of action have the potential to transform gout management. Panelists: Dr. Herbert Baraf Dr. Ken Saag Dr. Naomi Schlesinger Dr. Jack Cush (moderator)

Send us Fan MailIn this retrospective national study, Adrianne and Nim look at 25 years of congenital heart disease mortality in the US using CDC WONDER data. Infant mortality remains staggeringly high (54 per 100,000), and after years of steady decline, it has been climbing again since 2014. Disparities run throughout: higher deaths among males, non-Hispanic Black and American Indian/Alaska Native populations, and in rural, Midwestern regions, pointing more to gaps in access and resources than to disease biology. The conversation also flags a growing, under-discussed problem, an aging adult congenital population outpacing the pediatric one for the first time, with too few specialists trained to care for them.----National Trends and Disparities in Congenital Heart Disease Mortality in the United States, 1999-2024.Raja S, Albrahim MMS, Aldhafeeri BF, Omar AA, Alqadeeb BA, Alhuways MM, Bangaryd AA, Alqahtany MG, Alfaraj AB, Almughyir RS, AlRasheed ST, Alfaifi M. Pediatr Cardiol. 2026 Jan 13. doi: 10.1007/s00246-025-04156-1. Online ahead of print.PMID: 41528440Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below.Enjoy!

Send us Fan MailIn this systematic review and meta-analysis, Nim and Adrianne dig into just how common brain injury really is in neonates with critical congenital heart disease. Pooling 31 studies spanning two decades, the authors found that nearly 70% of these babies show some form of ischemic brain injury, split roughly between pre-operative and post-operative timing. Counter to what most clinicians would predict, kids who went to surgery earlier (days 4-6) had higher rates of white matter injury than those who waited longer. MRI remained the most sensitive tool for picking up these lesions, well ahead of ultrasound or CT. But the data stops well short of proving these findings predict long-term outcomes, and Nim pushes back on the idea that an abnormal scan alone should steer decisions about whether to operate.----Prevalence of Ischemic Brain Injury in Neonates With Congenital Heart Disease: A Systematic Review and Meta-Analysis.Kim C, Chetan D, Kazazian V, Alzamil J, Chau V, Seed M, Miller SP, Selvanathan T.Neurology. 2026 Feb 10;106(3):e214569. doi: 10.1212/WNL.0000000000214569. Epub 2026 Jan 9.PMID: 41512205Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below.Enjoy!

Send us Fan MailWhat if communication were treated as a procedure, something we train for and get feedback on, just like an intubation?  In this episode of Neo News, Eli Cahan talks with Dr. Jessica Fry of Northwestern University and Lurie Children's Hospital about her NeoReviews piece, "Recognizing Communication as a Procedural Skill in Neonatology." Dr. Fry shares the personal loss that shaped her career, the ethical stakes of getting family communication right, and how trauma-informed care can guide something as simple as how we address parents on rounds. They discuss the critical first 48 hours after admission and how simulation-based training can build real skill over time. A candid look at a skill every NICU provider uses daily, and how we can all get better at it. Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below.Enjoy!

Dr. Jimenez cites a 2024 Lancet study reporting a 79% rise in cancer among young adults globally between 1990 and 2019, with a 28% increase in deaths, across 17 cancer types. He attributes this to environmental toxins, obesity, diet, and early-life exposures, and names three top toxicities he targets in treatment: aluminum, glyphosate, and EMF radiation. He walks through daily detox practices (coffee enemas, shilajit, hydrogen water) and practical EMF-reduction steps (Wi-Fi off at night, phone away from the bed, grounding sheets). He explains when Hope4Cancer still uses chemo, radiation, or surgery — low-dose IPT chemo for tumor debulking, targeted "spot radiation" for pain control, and stents for obstructions — despite the clinic's non-toxic-first philosophy. He then details the clinic's "seven key principles," spending the most time on emotional/spiritual health (his upcoming book, Emotions and Cancer, out March 2025) and introduces Davida, a new five-part bioimmunotherapy meant to upregulate the immune system without targeting specific cancer-cell receptors (unlike checkpoint inhibitors such as Opdivo/Keytruda). Host Jim, a stage IV melanoma survivor, shares his own remission story, and Dr. Jimenez recommends he ask his oncologist about the Signatera circulating-tumor-cell test for ongoing monitoring.HealingStrong's mission is to educate, equip and empower our group leaders and group participants through their journey with cancer or other chronic illnesses, and know there is HOPE. We bring this hope through educational materials, webinars, guest speakers, conferences, community small group support and more.Please take advantage of our FREE resources below to help you along your health and healing journey:Support Group DirectoryHolistic Curriculum - Participant GuideSupport Our Mission - DonateAdditional Health ResourcesListen to Previous EpisodesWebsite: healingstrong.org

Dr Bill Nelson and Dr Mike Carducci examine the latest hormone target therapies for prostate cancer, their side effect profiles and the evolution of individualized treatments.

What do we miss by focusing only on seizure reduction in Dravet syndrome? Credit available for this activity expires: 7/21/27 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/dravet-syndrome-where-do-current-therapies-miss-mark-2026a1000o7r?ecd=bdc_podcast_libsyn_mscpedu

Send us Fan MailHow far has delivery room ventilation really come? In this special episode, recorded in collaboration with the Neonatal Resuscitation Symposium, Ben sits down with Dr. Charles Roehr, professor of neonatology and perinatal medicine at the University of Bristol, clinical trialist at the University of Oxford, and member of ILCOR. Together they trace the evolution of respiratory support at birth, from the era of fixed inflation breaths to today's focus on physiologic stability and gentle cardiopulmonary transition. Dr. Roehr reflects on a quarter century of resuscitation science, the enduring challenge of human factors in the delivery room, and where the field may be heading, from better intrapartum monitoring to increasingly specialized resuscitation teams.Dr. Roehr will be delivering a keynote, "Optimizing Effective Ventilation Strategies in the Delivery Room," at the Neonatal Resuscitation Symposium, taking place September 10 to 11 at Indiana University in Indianapolis. Learn more and register here: https://medicine.iu.edu/pediatrics/specialties/neonatal-perinatal/education/resuscitation-symposium Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below.Enjoy!

Send us Fan MailWhich PDAs actually need treatment? Can maternal voice and scent shape language outcomes? Should we cool at 35 weeks? And did stepping away from probiotics come at a cost? This week's Journal Club takes on five papers that push back on standard practice. Ben reviews the SMART-PDA trial and a comparative study of PDA pharmacotherapy, Daphna covers the MIND trial on multisensory maternal interventions and a Pediatrix database study on NEC after the FDA probiotic warning, and Ben rounds out the main segment with a national look at hypothermia in 35-week infants with HIE. Ben and Eli wrap the week with Neo News on rising vitamin K refusal.Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below.Enjoy!

Jordan and Nate open with a genuinely wild AI experiment: Nate ran his genetic data through an AI tool and got a full cognition, energy, and hormone report back. From there they dive deep into psychedelic therapy, celebrating RFK Jr.'s new HHS VA partnership researching psychedelics for veterans while flagging real concerns. Big Pharma is already circling, with Eli Lilly dropping billions to patent DMT based compounds, and the guys unpack a tragic Miami retreat case that shows why sketchy wellness grifters are just as dangerous as pharma control. They also roast a Wired writer who tried to "debunk" RFK's high protein advice by eating nothing but protein powders and pop tarts, dig into the mysterious diarrhea causing parasite showing up in lettuce, and cover a UK lab's synthetic fiber designed to hijack your GLP1 hormones. Rapid fire news on daylight saving time, baby formula ingredients, and a scary new screen time study rounds things out.

Send us Fan MailVitamin K refusal has crossed 5%. That's one in twenty babies, and the curve is bending the wrong way. Ben and Eli work through a new Pediatrics case review that opens with a warning shot, that hemorrhagic presentation in an infant should no longer be a diagnostic mystery, alongside a JAMA letter tracking refusal from 2.9% in 2017 to 5.2% in 2024. Eighty-one times the risk. Intracranial hemorrhage in most late-onset cases. Twenty percent mortality. They talk about the halo effect on other refusals, the ICD code you should be using, and why this conversation belongs in the obstetrics office, not the nursery.----Vitamin K Deficiency Bleeding After Refusal: A Sentinel Event in a Misinformation Era. Jacobs JW, Booth GS, Wheeler AP, Adkins BD.Pediatrics. 2026 May 1;157(5):e2026075994. doi: 10.1542/peds.2026-075994.PMID: 41916583 No abstract available.Trends in Vitamin K Administration Among Infants. Scott K, Miller E, Culhane JF, Greenspan J, Handley SC, Lo JY, Knake LA, McKenney KM, Burris HH, Dysart K.JAMA. 2026 Jan 20;335(3):272-274. doi: 10.1001/jama.2025.21460.PMID: 41359326 Free PMC article.Babies Are Bleeding to Death as Parents Reject a Vitamin Shot Given at Birth https://www.propublica.org/article/more-parents-decline-vitamin-k-shot-newbornsSupport the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below.Enjoy!

Send us Fan MailWhen the FDA warning landed in late 2023, probiotic use in high-use NICUs collapsed from 86% to under 7% almost overnight. What happened to NEC? This week Daphna brings Tolia and Patel's new Journal of Perinatology analysis of the Pediatrix Clinical Data Warehouse, a natural experiment across 347 NICUs and more than 10,000 extremely preterm infants. Centers that stopped saw NEC climb from 2.7% to 4.4%. Centers that never used probiotics saw nothing change. Ben and Daphna work through the difference-in-differences model, the demographic imbalances, and the uncomfortable question underneath it all. When does data stop and advocacy begin?----Probiotics and necrotizing enterocolitis in preterm infants after the food and drug administration warning actions. Tolia VN, Bennett MM, Handler D, Canvasser J, Greenberg RG, Ursprung R, Ahmad KA, Patel RM.J Perinatol. 2026 Jun 2. doi: 10.1038/s41372-026-02712-y. Online ahead of print.PMID: 42225922Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below.Enjoy!

Send us Fan MailCooling works at 36 weeks. At 35 weeks, nobody is sure. Ben brings a new Journal of Perinatology analysis of the National Inpatient Sample, covering 1.4 million infants from 2016 to 2022, asking what happens when therapeutic hypothermia is offered just below the evidence line. Cooled 35-weekers died at higher rates than cooled 36-weekers, but within the 35-week group, cooling changed nothing either way. Coagulopathy rose with cooling. Mediation analysis says it wasn't the cause. Ben and Daphna work through what that leaves us, and why shared decision making and careful documentation carry the weight here----Therapeutic hypothermia and in-hospital mortality in 35-week infants with encephalopathy. Aly H, Eltaly H, Mohamed FA, Saker F, Acun C, Mohamed MA.J Perinatol. 2026 Jun 3. doi: 10.1038/s41372-026-02738-2. Online ahead of print.PMID: 42236997Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below.Enjoy!

Send us Fan MailIn this Journal Club, Daphna takes the reins with the MIND randomized controlled trial from Nathalie Maitre and colleagues in The Journal of Pediatrics. Can a multisensory bundle, combining infant-directed voice, a parent's scent, holding, and gentle containment, do more for a preterm baby's developing brain than recorded voice alone? Using event-related potentials to track how infants tell speech sounds apart, the team followed language outcomes all the way to age two. Daphna and Ben unpack the design, the Bayley and PLS-5 findings, and a takeaway every clinician can act on tomorrow. Talk to the baby, every single time.----The MIND Randomized Controlled Trial: An Intervention to Improve Neural Speech Processing and 2-Year Language Outcomes of Infants Born Preterm. Maitre NL, Kjeldsen CP, Jeanvoine A, Lukemire J, Slaughter JL, Key AP.J Pediatr. 2026 Jun 5:115187. doi: 10.1016/j.jpeds.2026.115187. Online ahead of print.PMID: 42250747Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below.Enjoy!

Guest: In this special episode recorded live in Montréal, Canada at ISSCR 2026, Dr. Michael May, President and CEO of the Centre for Commercialization of Regenerative Medicine (CCRM), and Dr. Janet Rothberg, Senior Director of Process and Analytical Development at CCRM, explore how stem cell discoveries can be translated into commercially viable therapies through scalable manufacturing, company creation, investment, automation, and artificial intelligence. They emphasize the importance of considering manufacturing, quality control, market selection, reimbursement, and the evolving standard of care much earlier in the development process. They also share their vision for a future in which robust bioprocessing, better use of data, and improved regulatory and reimbursement models make iPSC-derived therapies more affordable and widely accessible.  Photo Reference: Courtesy of Drs. Michael May and Janet Rothberg Subscribe to our newsletter! Never miss updates about new episodes. Subscribe

Send us Fan MailIn this Journal Club, Ben and Daphna dig into two new papers on PDA management in our smallest patients. First, the SMART-PDA pilot RCT from Souvik Mitra and colleagues, which uses comprehensive hemodynamic screening to selectively treat high-volume shunts in infants born before 26 weeks, and whose striking Bayesian signal for reduced pulmonary hemorrhage and NEC stopped the trial early. Then a companion JAMA Network Open comparative effectiveness study across four pharmacotherapy regimens. Along the way, Ben shares hemodynamics pearls from his Montreal training: why left ventricular output, LA:Ao ratio, and transductal velocity matter more than PDA diameter alone.----Selective early medical treatment of the patent ductus arteriosus in extremely low gestational age infants: a pilot randomised controlled trial (SMART-PDA). Mitra S, Hebert A, Castaldo MP, Disher T, El-Naggar W, Dhillon S, Alhassen Z, Koo J, Katheria AC, Hyderi A, Kumaran K, Ting J, Surak A, Larocque J, Pepper D, Hornberger L, Makoni M, Weisz DE, Jain A, Bacchini F, Cameron-Nola AJJ, Hatfield T, Dorling J, McNamara PJ, Thabane L.Arch Dis Child Fetal Neonatal Ed. 2026 May 18:fetalneonatal-2026-330462. doi: 10.1136/archdischild-2026-330462. Online ahead of print.PMID: 42150872Pharmacologic Therapies for Patent Ductus Arteriosus in Extremely Preterm Infants. Mitra S, Jain A, Ting JY, Ben Fadel N, Drolet C, Abou Mehrem A, Soraisham AS, Jasani B, Louis D, Lapointe A, Dorling J, Khurshid F, Hyderi A, Kumaran K, Toye J, Harabor A, Weisz DE, Stavel M, Morin A, Bhattacharya S, Lalitha R, Afifi J, Augustine S, Castaldo MP, Hatfield T, Su YC, Shah PS; Canadian Neonatal Network Investigators.JAMA Netw Open. 2026 Jun 1;9(6):e2617477. doi: 10.1001/jamanetworkopen.2026.17477.PMID: 42262753 Free PMC article.Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below.Enjoy!

Broadcast from KSQD, Santa Cruz on 7-09-2026: Researchers refined a technique to reverse skin cell aging by about 30 years while preserving cellular identity. Exposing adult fibroblasts to Yamanaka factors—stopping before full reversion to pluripotent stem cells,reset the epigenetic clock and gene expression patterns to resemble much younger cells. The rejuvenated fibroblasts produced significantly more collagen, migrated faster to close artificial wounds, and showed reversal of gene expression patterns associated with Alzheimer's and cataracts. Since long-term epidemiologic data doesn't yet exist, Dr. Dawn follows up on last week's vaping question by exploring cancer mechanisms. Vaping aerosols impair DNA repair fidelity while triggering IL-6, IL-8, and TNF-alpha secretion. Nicotine-derived nitrosamines, reactive carbonyls (formaldehyde, acetaldehyde, acrolein) are generated when propylene glycol and vegetable glycerin are heated. Upregulated cytochrome P450 enzymes convert precarcinogens like benzopyrene into carcinogens. Mice exposed for 54 weeks developed lung adenocarcinomas in 22% and precancerous bladder hyperplasia in 57%, with markers matching those show predict lung cancer years before diagnosis. The Mexican Biobank—which includes over 40,000 samples from all 31 Mexican states revealed dramatic regional variation in drug-metabolism genes driven by Indigenous ancestry. In Chiapas, nearly 40% of the population carries two copies of a CYP2D6 variant reducing fentanyl metabolism, versus just 10% in Sinaloa. The SLCO1B1 variant hindering statin metabolism is found in over 15% of Yucatán residents., where 8 million Mexicans take statins. Dr. Dawn discusses both the promise and potential dark side of population genetic testing, including UK plans to genotype all children at birth for inborn errors of metabolism. Dr. Dawn briefly revisits the recent Indian study showing conch-shell blowing reduces sleep apnea by 34%, comparing it to earlier didgeridoo research, both of which strengthen airway muscles through forced-blowing exercises. A caller from Capitola recovering from non-Hodgkin's lymphoma near the L5 nerve asks about Japanese Kampo medicine formulas (Goshajinkigan, Yokukansan) for post-treatment nerve pain. Dr. Dawn suggests the pain likely originates from scar tissue tethering the nerve, and recommends consulting the Oriental Medicine Doctor program at Five Branches in Santa Cruz where faculty can advise on herbal formulas that trace back thousands of years through cultural exchange between China and Japan. Dr. Dawn explains Lp(a):lipoprotein(a), a small protein string attached to LDL particles that promotes clumping and clotting, is a genetically-determined coronary artery disease and stroke risk factor invisible to standard lipid panels. Levels of 250 particles double coronary risk and 350 particles triple it. Less than 75 is normal. Two new pharmaceutical strategies are in development to reduce Lp(a) : antisense oligonucleotides (single-stranded RNA that recruits RNase H to cleave target mRNA) and small interfering RNA (double-stranded RNA that triggers destruction of matching mRNA). Pelacarsen, a monthly injection in Phase 3 trials, reduces Lp(a) by 80%. These gene-silencing platforms open therapeutic possibilities for previously undruggable orphan diseases. Vitamin K2 is produced in the gut microbiome. MK-4 is most common in humans. Dr. Dawn recommends MK7 for stabilizing coronary calcium plaques and directing calcium into bone. A study of hepatitis B and C patients found MK4 to be protective in hepatocellular carcinoma. HCC developed in 2 of 21 MK-4-treated patients versus 9 of 19 controls, with a risk ratio of 0.2. MK-4 activates protein kinase A in vitro, inhibits HCC invasiveness, and restores apoptosis signaling that cancer cells normally block. Dr. Dawn recommends a couple milligrams of MK-4 daily for anyone with cirrhosis or prior hepatitis B or C infection.

Send us Fan MailIn this episode, Ben and Daphna sit down with Dr. Scott, pediatrician, neonatologist, and inventor of the Tortle. She shares how a simple observation in her Idaho practice, babies developing flat heads despite diligent parents, sparked a second career in medical device innovation. The conversation covers the evolution from the original corrective beanie to the Midliner and Transportal, the physiologic rationale for midline positioning in IVH prevention, and real-world data from a Tennessee children's hospital that cut its IVH rate from 28% to under 6%. She also offers candid advice for clinicians looking to turn an idea into a product.Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below.Enjoy!